Cas9 Null Mutant GFP NLS Protein (High Concentration)
351.99 €
In Stock
quantity
product details
Catalog number: 10021 - K186
Product Category: Business & Industrial > Science & Laboratory
Gentaur
Size: 47µg (250pmol) Volume: 25µL
K186
Cas9 Null Mutant GFP NLS Protein (High Concentration)
The Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 system is the latest RNA-guided, endonuclease tool in genome editing which allows for very specific genomic disruption and replacement. ;The Cas9 Null Mutant Protein is created by mutating both cleavage domains of the wild type Cas9 (D10A and H840A). Such a Cas9 protein retains its ability to bind to genomic DNA through gRNA:genomic DNA base pairing, however, unlike Cas9 Nuclease and Cas9 Nickase, where permanent gene disruption can be achieved, the Cas9 Null Mutant does not introduce any genome modifications. Therefore, this protein can provide a useful negative control for CRISPR experiments. In addition, binding of the Null Mutant can act as a roadblock to hinder transcription, thus offering a useful tool to achieve reversible knock-down of gene expression. ;The Cas9 from the bacteria <i>Streptococcus pyogenes</i>, abbreviated spCas9, is the most commonly used Cas9 variant. ;The fusion of Cas9 to GFP allows for visual confirmation of transfection as well as subsequent verification of Cas9 clearance from the cells. Cas9 Null Mutant GFP can also be used for FACS applications and screening. Cas9 D10A Null Mutant GFP NLS contains a SV40 T antigen nuclear localization sequence (NLS) on the C-terminus of the protein.
351.99 €
K142
Cas9 Null Mutant NLS Protein (High Concentration)
The Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 system is the latest RNA-guided, endonuclease tool in genome editing which allows for very specific genomic disruption and replacement. ;;The Cas9 Null Mutant Protein is created by mutating both cleavage domains of the wild type Cas9 (D10A and H840A). Such a Cas9 protein retains its ability to bind to genomic DNA through gRNA:genomic DNA base pairing, however, unlike Cas9 Nuclease and Cas9 Nickase, where permanent gene disruption can be achieved, the Cas9 Null Mutant does not introduce any genome modifications. Therefore, this protein can provide a useful negative control for CRISPR experiments. In addition, binding of the Null Mutant can act as a roadblock to hinder transcription, thus offering a useful tool to achieve reversible knock-down of gene expression.;;The Cas9 nuclease from the bacteria <i>Streptococcus pyogenes</i>, abbreviated spCas9, is the most commonly used Cas9 variant. The reason for spCas9 popularity is two-fold. First the spCas9 PAM sequence is 5’-NGG, which is highly abundant in the genome allowing virtually any gene to be targeted. The spCas9 enzyme also has on average a higher efficiency <i>in vivo </i>compared to other variants. Cas9 Null Mutant NLS contains a SV40 T antigen nuclear localization sequence (NLS) on the C-terminus of the protein.
321.69 €
K147
saCas9 Null Mutant NLS Protein (High Concentration)
The Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 system is the latest RNA-guided, endonuclease tool in genome editing which allows for very specific genomic disruption and replacement. ;;The saCas9 Null Mutant Protein is created by mutating both cleavage domains of the wild type saCas9. Such a saCas9 protein retains its ability to bind to genomic DNA through gRNA:genomic DNA base pairing, however, the saCas9 Null Mutant does not introduce any genome modifications. Therefore, this protein can provide a useful negative control for CRISPR experiments. In addition, binding of the Null Mutant can act as a roadblock to hinder transcription, thus offering a useful tool to achieve reversible knock-down of gene expression.;; The Cas9 nuclease from the bacteria <i>Staphylococcus aureus</i>, abbreviated saCas9, is gaining popularity as an alternative to spCas9 due to its relatively smaller size. The saCas9 PAM sequence is 5’-NNGRRN (preferably 5’-NNGRRT). saCas9 NLS Null Mutant contains a SV40 T antigen nuclear localization sequence (NLS) on the C-terminus of the protein.
351.99 €